Segui
Blank c
Blank c
Email verificata su nki.nl
Titolo
Citata da
Citata da
Anno
Pembrolizumab versus ipilimumab in advanced melanoma
C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
New England Journal of Medicine 372 (26), 2521-2532, 2015
57742015
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
A Hauschild, JJ Grob, LV Demidov, T Jouary, R Gutzmer, M Millward, ...
The Lancet 380 (9839), 358-365, 2012
34682012
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
EM Van Allen, D Miao, B Schilling, SA Shukla, C Blank, L Zimmer, ...
Science 350 (6257), 207-211, 2015
26752015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ...
The lancet oncology 16 (8), 908-918, 2015
17442015
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ...
New England Journal of Medicine 378 (19), 1789-1801, 2018
17212018
B cells and tertiary lymphoid structures promote immunotherapy response
BA Helmink, SM Reddy, J Gao, S Zhang, R Basar, R Thakur, K Yizhak, ...
Nature 577 (7791), 549-555, 2020
16312020
LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells
A Brand, K Singer, GE Koehl, M Kolitzus, G Schoenhammer, A Thiel, ...
Cell metabolism 24 (5), 657-671, 2016
13062016
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
D Nejman, I Livyatan, G Fuks, N Gavert, Y Zwang, LT Geller, ...
Science 368 (6494), 973-980, 2020
12602020
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
J Schachter, A Ribas, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
The Lancet 390 (10105), 1853-1862, 2017
12602017
Defining ‘T cell exhaustion’
CU Blank, WN Haining, W Held, PG Hogan, A Kallies, E Lugli, RC Lynn, ...
Nature Reviews Immunology 19 (11), 665-674, 2019
10182019
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
C Blank, I Brown, AC Peterson, M Spiotto, Y Iwai, T Honjo, TF Gajewski
Cancer research 64 (3), 1140-1145, 2004
10182004
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
C Robert, A Ribas, J Schachter, A Arance, JJ Grob, L Mortier, A Daud, ...
The Lancet Oncology 20 (9), 1239-1251, 2019
9922019
Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma
C Sun, L Wang, S Huang, GJJE Heynen, A Prahallad, C Robert, ...
Nature 508 (7494), 118-122, 2014
8752014
Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma
H Li, AM van der Leun, I Yofe, Y Lubling, D Gelbard-Solodkin, ...
Cell 176 (4), 775-789. e18, 2019
8192019
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
C Blank, TF Gajewski, A Mackensen
Cancer Immunology, Immunotherapy 54, 307-314, 2005
8012005
The “cancer immunogram”
CU Blank, JB Haanen, A Ribas, TN Schumacher
Science 352 (6286), 658-660, 2016
7682016
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
PA Ascierto, D Schadendorf, C Berking, SS Agarwala, CML van Herpen, ...
The lancet oncology 14 (3), 249-256, 2013
7502013
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
CU Blank, EA Rozeman, LF Fanchi, K Sikorska, B van de Wiel, ...
Nature medicine 24 (11), 1655-1661, 2018
7012018
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
L Voorwerk, M Slagter, HM Horlings, K Sikorska, KK van de Vijver, ...
Nature medicine 25 (6), 920-928, 2019
6942019
Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion
C Blank, A Mackensen
Cancer immunology, immunotherapy 56, 739-745, 2007
6432007
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20